name

õ¿¬¹°¿¡¼­ ±â´É¼º¼ÒÀ縦 °³¹ßÇÏ¿© »óÇ°È­ÇÏ´Â Àü¹®Áö½Ä°ú ±â¼ú·ÂÀ¸·Î õ¿¬¹ÙÀÌ¿À»ê¾÷ÀÇ ¹Ì·¡¸¦ °³Ã´ÇØ ³ª¾Æ°©´Ï´Ù
EstroG-100¢ç
ME.NO.PAUSE.
EstroG-100¢ç

EstroG-100¢ç(¹é¼ö¿À µî º¹ÇÕÃßÃâ¹°)Àº ¹é¼ö¿À, ÇѼӴÜ, ´ç±Í¸¦ ¹èÇÕÇÑ ±¹³» ÃÖÃÊ ½Ä¾àó ¿©¼º °»³â±â ±â´É¼º ÀÎÁ¤ ¿ø·áÀÔ´Ï´Ù.
´Ù¼öÀÇ ÀÎüÀû¿ë½ÃÇè ¹× ¿¬±¸³í¹®À» ÅëÇØ 10°¡Áö °»³â±â Áõ»ó °³¼± È¿°ú¸¦ È®ÀÎÇÏ¿´À¸¸ç
ƯÈ÷ ¿¡½ºÆ®·Î°Õ ¼öÄ¡(E2, FSH)¿¡ ¿µÇâÀÌ ¾ø°í, ¿¡½ºÆ®·Î°Õ ¼ö¿ëü¿¡ °áÇÕÇÏÁö ¾Ê¾Æ ¿©¼º ÁúȯÀ¸·ÎºÎÅÍ ¾ÈÀüÇÏ°Ô ¼·ÃëÇÒ ¼ö ÀÖ½À´Ï´Ù.
¶ÇÇÑ ¹Ì±¹ FDA ±â´É¼º ¹°Áú(NDI) ÀÎÁõ, ij³ª´Ù ½Ä¾àû õ¿¬•±â´É¼º ¹°Áú(NPN) ¶óÀ̼±½º ȹµæ, À¯·´½ÄÇ°¾ÈÀüû ³ëºíǪµå Åë°ú µîÀ» ÅëÇØ
Àü ¼¼°èÀûÀ¸·Î ¸¹Àº Áß³â ¹× ³ë³â±â ¿©¼ºµéÀÇ »ç¶ûÀ» ¹Þ°í ÀÖ½À´Ï´Ù.

Exclusivity

±Û·Î¹ú ƯÇã ȹµæ ÇöȲ
ƯÇã ¸íĪ: Æó°æ±â Áõ»óÀÇ ¿¹¹æ ¶Ç´Â Ä¡·á¿ë ½Ä¹°¼º ¿¡½ºÆ®·Î°Õ Á¶¼º¹°
(Phytoestrogenic Compositions for Preventing or Treating Symptoms Associated with Menopause)
±Û·Î¹ú ƯÇã ȹµæ ÇöȲ¿¡ °ü·Ã µÈ Ç¥
±¹°¡ µî·Ï¹øÈ£ ±¹°¡ µî·Ï¹øÈ£
´ëÇѹα¹ 10-1141194 À¯·´(µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ½ºÆäÀÎ, ÀÌÅ»¸®¾Æ, Æú¶õµå) 2370072
¹Ì±¹ 9,433,595
ij³ª´Ù 2745020 ¸ß½ÃÄÚ 328059
·¯½Ã¾Æ 2491926 ¸»·¹ÀÌ½Ã¾Æ MY-184493-A
Áß±¹ ZL200880132506.0 Àεµ³×½Ã¾Æ ID.P.000050866
È£ÁÖ 2008365666 ºê¶óÁú PI0823391-8

Approval

±Û·Î¹ú ƯÇã ȹµæ ÇöȲ¿¡ °ü·Ã µÈ Ç¥
±¹°¡ ÀÎÇã°¡¸í
¹Ì±¹ New Dietary Ingredient
ij³ª´Ù Natural Health Product
À¯·´ Novel Food Ingredient
ÀϺ» ½Ä¾à±¸ºÐÁ¶È¸
¸»·¹ÀÌ½Ã¾Æ Food Supplement, Traditional Medicine
Çʸ®ÇÉ Herbal Medicine
Àεµ Food for Special Dietary Use
À̶õ Natural Product
ÀÌÁýÆ® Herbal Medicine Product

Mechanism of Action

¿¡½ºÆ®·Î°Õ È°¼ºÀ¸·Î ÀÎÇÑ ºÎÀÛ¿ë ¾øÀÌ ¾ÈÀüÇÏ°Ô 10°¡Áö °»³â±â Áõ»ó °³¼±
No adverse event at all subjects
No change in weight, BMI and liver enzymes
No change in serum E2 & FSH
No influence on estrogen-sensitive tissues
No binding affinities for ER¥á, ER¥â, and nonselective ER
No toxic effects shown in toxicity studies

5 Human clinical studies published

KMI(Kupperman menopause index, °»³â±âÁö¼ö) 62% °³¼±
10°¡Áö °»³â±â Áõ»ó °³¼±(¾È¸éÈ«Á¶ ¹× ¹ßÇÑ, ¼Õ¹ßÀú¸², ºÒ¸éÁõ, ½Å°æÁú, ¿ì¿ïÁõ, ¾îÁö·³Áõ, ÇǷΰ¨, °üÀý ¹× ±ÙÀ°Åë, ÀÇÁÖ°¨, Áú °ÇÁ¶)¡Ø Phytother. Res. 2012, 26:510-6.
40~70¼¼ ¿©¼º 60¸í ´ë»ó 12ÁÖ ¼·Ãë
EstroG-100¢ç ¼·Ãë ¸¸Á·µµ
°»³â±â Áõ»ó °³¼± Àü¹ÝÀû ¸¸Á·µµ 100%J Midlife Health. 2023, 14:285-290.

Numerous in vitro & in vivo studies

¾È¸éÈ«Á¶
  • Tail skin temperature (TST) ¡é
°ñ´Ù°øÁõ
  • Femoral bone mineral density ¡è
ºÒ¸éÁõ
  • Sleep induction time ¡é
  • Sleep continuity time ¡è
  • Recovery time ¡é
  • Melatonin in plasma & GABA in brain ¡è
¿ì¿ïÁõ
  • Behavior evaluation ¡è
  • Serotonin & dopamine in brain¡è
  • Corticosterone in serum ¡è
°üÀý¿°
  • Edema rate¡é
  • Cartilage maintenance factors (Col2¥á1, Aggrecan, Proteoglycan, SOX-9, Collagen I, Collage X) ¡è
  • Cartilage destruction factors (TIMP-1, MMP3, MMP7) ¡é
  • Degenerative osteoarthritis inducing factors (COX-2, MMP, NF-¥êB, TNF-¥á, IL-1¥â) ¡é
ÇÇ·Î
  • Glycogen content in muscle ¡è
  • LDH activity in muscle ¡é
  • Genetic expression of exercise fatigue recovery factors (PPAR-¥ä, UCP-3) ¡è
  • Antioxidant enzyme activity (SOD, CAT, GST) ¡è
  • Antioxidant compounds in liver (GSH) ¡è
  • Oxidative stress marker in liver (MDA) ¡é

Recommended dosage

175 ~ 514 mg/day